 |
| Wockhardt's headquarters in Mumbai, India--Courtesy of Wockhardt |
Executives at India's Wockhardt insist the troubled generics maker is not for sale--nada, no way. But that has not stopped analysts from discussing matchmaking, especially since execs at India's Lupin acknowledged recently that they analyzed whether buying Wockhardt would make sense. The analysts are suggesting some of the usual suspects: Teva Pharmaceutical Industries ($TEVA), Actavis ($ACT) and Mylan ($MYL). While Wockhardt has two of its plants banned by the FDA, analysts tell Bloomberg the right buyer might want the company just to get access to its extensive business in India, one of the faster growing global markets. Report | More